COMT
Catechol O-methyltransferase
As of the edition of 20 October 2026, COMT (catechol O-methyltransferase, UniProt P21964) has 4 drugs tested at it and 9 companies on the list, 1 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P21964
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 12
- Disease areas
- Nervous system; Mental health; Chemically induced; Cancer; Nutrition and metabolism; Injuries; Digestive system; Heart and blood vessels
- Registered trials of its drugs
- 112
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Went quiet | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Opicapone | Marketed | Phase 4 | Ends 2032 |
| Entacapone | Marketed | Phase 4 | none listed |
| Tolcapone | Marketed | Phase 4 | none listed |
| Nebicapone | Went quiet | Phase 2 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 3 |
| Engaged | 2 |
| Undetermined | 3 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| Ono Pharmaceutical | Route B |
| Roche | Route A |
| Novartis | Route B |
The other 6 companies at COMT
In the product9 companies in all; 6 are not named here, and no score is.
See the 9 companies at COMT, ranked, with the facts behind eachRequest access. Nothing is shown until you do.